Refractory Partial-Onset Seizures Reduced by Adjunctive Rufinamide

$Refractory Partial-Onset Seizures Reduced by Adjunctive Rufinamide$

Treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS), researchers from the Arkansas Epilepsy Program have found.

Details of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Epilepsy affects up to 2% of the worldwide population according to the Centers for Disease Control and Prevention. More than half of these patients experience POS, or focal seizures, which are initiated in one part of the brain. Despite an expanding number of antiepileptic drugs (AEDs) available to treat partial-onset epilepsy, about one-third of epilepsy patients remain resistant to available treatments and many more experience intolerable side effects, driving the search for therapeutic alternatives. The current study evaluated rufinamide, an AED with a novel triazole-derivative structure, to confirm its efficacy and safety at a dose of 1,600 mg twice daily as adjunctive treatment for refractory POS.

Eligible patients were male or female, aged 12-80 years, with POS with or without secondarily generalized seizures. Patients' seizures were inadequately controlled on stable doses of up to three concomitantly administered AEDs, with no evidence of AED treatment noncompliance. All medication taken regularly by patients, including AEDs, remained unchanged for at least 1 month prior to study start and throughout the study. Patients were enrolled at 61 centers in the U.S. and at four centers in Canada between February 2006 and March 2009. In total, 357 patients were randomly assigned to receive rufinamide (n = 176) or placebo (n = 181) and entered the titration phase, and 139 and 156 patients, respectively, completed the study. This study comprised a 56-day baseline phase (BP), 12-day titration phase, and 84-day maintenance phase (MP).

The researchers found that treatment with rufinamide resulted in a statistically significant reduction in total partial seizure frequency compared with placebo. Results also showed a 50% reduction in responder rate and total partial seizure frequency rate in patients treated with rufinamide. Several exploratory efficacy variables, including at least 75% responder rate and increase in the number of seizure-free days, were also associated with notably better results for rufinamide.

With respect to efficacy by seizure type, rufinamide was significantly superior to placebo for complex partial seizures, the most common seizure type, and numerically superior to placebo for simple partial seizures and secondarily generalized partial seizures. The median reduction in secondarily generalized partial seizures of 40% in this study is consistent with that previously observed at identical rufinamide dosage.

Study leader Victor Biton, M.D., comments, "Overall, there were no significant pharmacokinetic (PK) effects on either rufinamide or any second-generation AED when given with other medications." The research team confirmed PK results found in previous studies—showing lower oral bioavailability of rufinamide at higher doses, increased clearance of rufinamide with increasing body weight, and no effect of prolonged rufinamide dosing on the PK of rufinamide."

"Our study demonstrates that rufinamide is effective as adjunctive therapy in reducing total partial seizure frequency in treatment-refractory adolescent and adult patients, and confirms the known safety and tolerability profile of rufinamide in this patient population," concludes Dr. Biton.

Source: Eurekalert

Epilepsy

Fits or convulsions or Epilepsy is characterized by recurrent, involuntary seizures and is described as a chronic neurological disorder

Neurocysticercosis

Neurocysticercosis or Cysticercosis of brain is the most common cause of epilepsy and the most common parasitic infection of the brain. Neurocysticercosis is more common in the developing countries.

Epilepsy and Slides - Animation

Epilepsy is a medical condition where the brain cells fire abnormal electrical signals that physically manifests as a 'Seizure'. There should be two or more seizures before the term epilepsy should be used.

Absence Seizure

Absence seizure (petit mal epilepsy) involves sudden lapse in consciousness and staring blankly into space, the episodes lasting less than 15 seconds.

Aicardi-Goutieres Syndrome

Aicardi-Goutieres Syndrome is observed in infants and older children. To date, defects in 6 genes are known to cause the syndrome. Irritability, erratic sleep, and fever are some symptoms.

Convulsions

A seizure or a convulsion is a result of abnormal electrical activity in the brain. However, not all convulsions amount to epilepsy, and it can affect an individual at any age.

DOOR Syndrome / Rare Genetic Disorder

DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal development of digits, and intellectual impairment. It is non-progressive and treatment is mainly supportive.

Epilepsy In Children / Seizures In Children

Epilepsy or seizures are caused by abnormal electrical activity in the brain and seen fairly commonly in children. Symptoms can be highly variable and parents should seek prompt medical advice to treat the condition

Focal Seizures (Partial Seizures)

Focal or partial seizures are abnormal localized electrical discharges in the brain. They are of two types and exhibit many associated symptoms. Focal seizures can be diagnosed by EEG and brain imaging and treated with drugs and lifestyle changes.

Video-EEG Monitoring Test

Video-electroencephalography monitoring is a diagnostic technique that records the electrical activity of the brain during seizures for a prolonged period.